Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Thomas D. Madden
Advertisement
Thomas D. Madden, PhD, is CEO of Acuitas Therapeutics.
Articles by Thomas D. Madden
Advertisement
Latest Updated Articles
Advertisement
Advertisement